

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI142797

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	1
CONVEYING PARTY DATA	
Name	Execution Date
ASTRAZENECA AB	03/21/2024
RECEIVING PARTY DATA	
Company Name:	APT THERAPEUTICS INC
Street Address:	1701 Quincy Ave, Unit 21
City:	Naperville,
State/Country:	ILLINOIS
Postal Code:	60540,
PROPERTY NUMBERS Total: 7	
Property Type	Number
Application Number:	10703780
Application Number:	12145394
Application Number:	11069543
Application Number:	13522310
Application Number:	13522311
Application Number:	14666121
Application Number:	17905540
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8087817933
Email:	nfedde@feddelaw.com,kfedde@feddelaw.com
Correspondent Name:	Nathaniel Kenton Fedde
Address Line 1:	18325 Allenton Woods Ct
Address Line 4:	Wildwood, MISSOURI 63069
ATTORNEY DOCKET NUMBER:	APT_ASSIGNMENTS
NAME OF SUBMITTER:	Nathaniel Fedde
SIGNATURE:	Nathaniel Fedde

DATE SIGNED:	04/03/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).
Total Attachments: 5 source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif source=Assignment#page4.tif source=Assignment#page5.tif	

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 21 March 2024 (the “Effective Date”) by and between

ASTRAZENECA AB, a company incorporated in Sweden under No. 556011-7 482 with registered office is at SE-151 85 Södertälje, Sweden (“Assignor”); and

APT THERAPEUTICS INC, a company incorporated in the USA with offices at 1701 Quincy Ave, Unit 21, Naperville, IL 60540, USA (“Assignee”).


WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “Applications”) and in and to the inventions and improvements disclosed in such Applications.


NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:


1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.


5. This assignment shall be governed by and construed in accordance with the laws of the State of New York, USA, and the parties hereby submit to the exclusive jurisdiction of the courts of the State of New York and the United States District Court for the District of New York.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


Signed for and on behalf of
AstraZeneca AB
Name: *Peter Storm*
Title: Authorised Signatory


Witnessed by Fabricio Belgrano
Date: *21 March 2024*


Signed for and on behalf of
APT Therapeutics Inc
Name: Ridong Chen
Title: Authorised Signatory


Witnessed by Soon Seong Jeong, PhD
Date: *21 March 2024*

THE SCHEDULE

Country	Current Status	Filing	Filing Number	Publication	Publication No.	Grant Number
United States Of America	Grant	07 Nov 2003	10/703,780			7,247,300
Switzerland	Grant	17 Jun 2009	09162974.1	16 Dec 2009	2133430	2133430
Germany	Grant	17 Jun 2009	09162974.1	16 Dec 2009	2133430	60 2005 045 484.5
European Procedure (Patents)	Abandoned (Killer Event)	28 Feb 2005	05724164.8	20 Dec 2006	1733045	
European Procedure (Patents)	Grant	17 Jun 2009	09162974.1	16 Dec 2009	2133430	2133430
France	Grant	17 Jun 2009	09162974.1	16 Dec 2009	2133430	2133430
United Kingdom	Grant	17 Jun 2009	09162974.1	16 Dec 2009	2133430	2133430
Sweden	Grant	17 Jun 2009	09162974.1	16 Dec 2009	2133430	2133430
United States Of America	Grant	24 Jun 2008	12/145,394	05 Feb 2009	US 2009-0035291 A1	8,021,866
United States Of America	Grant	28 Feb 2005	11/069,543	29 Sep 2005	US 2005-0215505 A1	7,390,485
International Procedure	Converted (Killer Event)	28 Feb 2005	PCT/US2005/006568	15 Sep 2005	WO 2005/085468	
United States Of America	Grant	13 Jan 2011	13/522,310	31 Jan 2013	US 2013-0028880 A1	8,535,662
International Procedure	Converted (Killer Event)	13 Jan 2011	PCT/US2011/021170	21 Jul 2011	WO 2011/088231	
Brazil	Filing	13 Jan 2011	BR112012017243-3			
Canada	Grant	13 Jan 2011	2,787,016			2,787,016
Switzerland	Grant	13 Jan 2011	11733394.8	21 Nov 2012	2523971	2523971
Germany	Grant	13 Jan 2011	11733394.8	21 Nov 2012	2523971	602011014025.6
European Procedure (Patents)	Grant	13 Jan 2011	11733394.8	21 Nov 2012	2523971	2523971
France	Grant	13 Jan 2011	11733394.8	21 Nov 2012	2523971	2523971

United Kingdom	Grant	13 Jan 2011	11733394.8	21 Nov 2012	2523971	2523971
Ireland	Grant	13 Jan 2011	11733394.8	21 Nov 2012	2523971	2523971
Japan	Grant	13 Jan 2011	2012-549089			5913130
United States Of America	Grant	13 Jan 2011	13/522,311	06 Jun 2013	US 2013-0142775 A1	8,771,683
International Procedure	Converted (Killer Event)	13 Jan 2011	PCT/US2011/021187	21 Jul 2011	WO 2011/088244	
China	Publication of Application	23 Apr 2014	201410172357.8	11 Nov 2015	CN 105018442 A	
United States Of America	Abandoned (Killer Event)	23 Mar 2015	14/666,121	24 Sep 2015	US 2015-0265685 A1	
United Arab Emirates	Local filing	05 Mar 2021	PG001746/2022			
Argentina	Publication of Application	05 Mar 2021	P210100577	07 Sep 2022	AR122391 A1	
Australia	Local filing	05 Mar 2021	2021230101			
Bahrain	Local filing	05 Mar 2021	20220284			
Brazil	Publication of Application	05 Mar 2021	BR112022017821-2	31 Jan 2023	2717	
Canada	Local filing	05 Mar 2021	3173750			
Chile	Publication of Application	05 Mar 2021	CL 202202406	14 Apr 2023		
China	Publication of Application	05 Mar 2021	202180019344.5	25 Oct 2022	115243710	
Colombia	Publication of Application	05 Mar 2021	NC2022/0013678	11 Oct 2022	976	
Costa Rica	Publication of Application	05 Mar 2021	2022-503	28 Nov 2022		
Eurasian Procedure	Local filing	05 Mar 2021	202292432			
Ecuador	Publication of Application	05 Mar 2021	2022-77003	30 Nov 2022		
Egypt	Local filing	05 Mar 2021	1250/2022			
European Procedure (Patents)	Publication of Application	05 Mar 2021	21710268.0	11 Jan 2023	4114443	

Guatemala	Publication of Application	05 Mar 2021	A-2022-0200	05 Jul 2023	
Hong Kong	Publication of Application	05 Jul 2023	62023075441.3	25 Aug 2023	40086605 A
Indonesia	Local filing	05 Mar 2021	P00202210832		
Israel	Local filing	05 Mar 2021	295998		
India	Local filing	05 Mar 2021	202217055005		
Japan	Publication of Application	05 Mar 2021	2022-552895	18 Apr 2023	2023-516196
South Korea / Republic of Korea	Local filing	05 Mar 2021	10-2022-7034472		
Kuwait	Local filing	05 Mar 2021	KW/P/2022/001373		
Mexico	Local filing	05 Mar 2021	MX/a/2022/011079		
Malaysia	Local filing	05 Mar 2021	PI 2022004812		
New Zealand	Local filing	05 Mar 2021	793081		
Oman	Local filing	05 Mar 2021	OM/P/2022/000448		
Philippines	Local filing	05 Mar 2021	1-2022-552305		
Qatar	Local filing	05 Mar 2021	QA/202209/00581		
Saudi Arabia	Local filing	05 Mar 2021	522440416		
Singapore	Local filing	05 Mar 2021	11202252647T		
Thailand	Local filing	05 Mar 2021	2201005605		
Taiwan	Publication of Application	23 Feb 2021	110106225	16 Dec 2021	202146042
Ukraine	Local filing	05 Mar 2021	a202203533		
United States Of America	Publication of Application	05 Mar 2021	17/905,540	20 Apr 2023	US-2023-0119254-A1
Vietnam	Local filing	05 Mar 2021	1-2022-06411		
International Procedure	Converted (Killer Event)	05 Mar 2021	PCT/EP2021/055558	10 Sep 2021	WO 2021/176038
South Africa	Local filing	05 Mar 2021	2022/10876		

PATENT

REEL: 066997 FRAME: 0910

RECORDED: 04/03/2024